Trials / Recruiting
RecruitingNCT07089121
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Cartesian Therapeutics · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Conditions
- Childhood-onset Systemic Lupus Erythematous
- ANCA-Associated Vasculitis (AAV)
- Juvenile Myasthenia Gravis
- Juvenile Dermatomyositis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Descartes-08 | In part 1, three different doses will be administered to 3 participants with either disease indication to establish maximum tolerated dose In part 2, the MTD established in Part-1 will be administered as six once-weekly infusions to up to 10 participants per each of four baskets (cSLE, AAV, JDM and JMG) in an outpatient setting. |
Timeline
- Start date
- 2026-01-14
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
- First posted
- 2025-07-28
- Last updated
- 2026-04-08
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07089121. Inclusion in this directory is not an endorsement.